AP
PETX

Alydar Partners’s Aratana Therapeutics, Inc. PETX Stock Holding History

Alydar Partners’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-180,000
Closed -$2.81M – 146
2014
Q2 		$2.81M Buy
+180,000
New +$2.55M 0.24% 75

Other funds holding PETX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Alydar Partners's PETX Position: Q3 2014 in Review

Alydar Partners sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2014, closing a stake of 180,000 shares — an estimated $2.81M sold.

Alydar Partners first reported a position in PETX in Q2 2014 and held it in 1 quarter. The position peaked at $2.81M in Q2 2014. 82 funds tracked by Wall St. Rank hold PETX as of Q3 2014.

  • Alydar Partners reported no remaining Aratana Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Alydar Partners sold 180,000 Aratana Therapeutics, Inc. shares in Q3 2014, an estimated $2.81M.
  • Alydar Partners first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Alydar Partners's Aratana Therapeutics, Inc. position peaked at $2.81M in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2014.

Based on Alydar Partners's 13F filing for Q3 2014, filed 14 Nov 2014.